Prediction of disease-free survival by the PET/CT radiomic signature in non-small cell lung cancer patients undergoing surgery

  • Margarita Kirienko
  • Luca Cozzi
  • Lidija Antunovic
  • Lisa Lozza
  • Antonella Fogliata
  • Emanuele Voulaz
  • Alexia Rossi
  • Arturo Chiti
  • Martina Sollini
Original Article

Abstract

Purpose

Radiomic features derived from the texture analysis of different imaging modalities e show promise in lesion characterisation, response prediction, and prognostication in lung cancer patients. The present study aimed to identify an images-based radiomic signature capable of predicting disease-free survival (DFS) in non-small cell lung cancer (NSCLC) patients undergoing surgery.

Methods

A cohort of 295 patients was selected. Clinical parameters (age, sex, histological type, tumour grade, and stage) were recorded for all patients. The endpoint of this study was DFS. Both computed tomography (CT) and fluorodeoxyglucose positron emission tomography (PET) images generated from the PET/CT scanner were analysed. Textural features were calculated using the LifeX package. Statistical analysis was performed using the R platform. The datasets were separated into two cohorts by random selection to perform training and validation of the statistical models. Predictors were fed into a multivariate Cox proportional hazard regression model and the receiver operating characteristic (ROC) curve as well as the corresponding area under the curve (AUC) were computed for each model built.

Results

The Cox models that included radiomic features for the CT, the PET, and the PET+CT images resulted in an AUC of 0.75 (95%CI: 0.65–0.85), 0.68 (95%CI: 0.57–0.80), and 0.68 (95%CI: 0.58–0.74), respectively. The addition of clinical predictors to the Cox models resulted in an AUC of 0.61 (95%CI: 0.51–0.69), 0.64 (95%CI: 0.53–0.75), and 0.65 (95%CI: 0.50–0.72) for the CT, the PET, and the PET+CT images, respectively.

Conclusions

A radiomic signature, for either CT, PET, or PET/CT images, has been identified and validated for the prediction of disease-free survival in patients with non-small cell lung cancer treated by surgery.

Keywords

Radiomics Lung cancer Prognosis CT PET/CT Texture analysis 

Notes

Acknowledgements

We thank Elena Vanni for support in patient selection; Paola Bossi and Dahoud Rahal for collaboration in pathological analyses; Marco Alloisio, Giulia Veronesi and the Thoracic Surgery Unit for close collaboration in patient selection and follow-up; Lorenzo Leonardi for image processing; and Riccardo Muglia, Nicolò Gennaro and Orazio Giuseppe Santonocito for their help in patient selection.

M.K. is supported by the AIRC (Italian Association for Cancer Research) scholarship funded by the grant won by A.C. (IG-2016-18585).

Author contributions

M.S., M.K. and A.C. conceived the idea of the study; L.C., L.L. and A.F. performed the statistical analysis; E.V. collected the data and selected the patients; M.S., M.K. and L.A. reviewed and segmented the images; L.C. performed image analysis; M.S., M.K. and L.C. wrote the manuscript; A.R. edited and reviewed the manuscript.

All the authors discussed the results and commented on the manuscript.

Compliance with ethical standards

Disclosure of potential

A. Chiti received speaker honoraria from General Electric and Sirtex Medical System, acted as scientific advisor for Blue Earth Diagnostics and benefited from an unconditional grant from Sanofi to Humanitas University. All honoraria and grants are outside the scope of the submitted work.

L. Cozzi acts as Scientific Advisor to Varian Medical Systems. All honoraria are outside the scope of the submitted work.

M. Kirienko is supported by the AIRC (Italian Association for Cancer Research) scholarship funded by the grant won by A.C. (IG-2016-18,585).

Conflict of interest

All other authors have no conflicts of interest.

Research involving human participants

The study was approved by the institutional Ethics Committee. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

For this type of study formal consent was not required.

Supplementary material

259_2017_3837_MOESM1_ESM.docx (25 kb)
ESM 1 (DOCX 25 kb)
259_2017_3837_Fig5_ESM.gif (28 kb)
Supplementary Fig. 1

(GIF 27 kb)

259_2017_3837_MOESM2_ESM.tiff (99.7 mb)
High resolution image (TIFF 102048 kb)
259_2017_3837_Fig6_ESM.gif (174 kb)
Supplementary Fig. 2

(GIF 173 kb)

259_2017_3837_MOESM3_ESM.tiff (255.5 mb)
High resolution image (TIFF 261601 kb)
259_2017_3837_Fig7_ESM.gif (144 kb)
Supplementary Fig. 3

(GIF 143 kb)

259_2017_3837_MOESM4_ESM.tiff (255.5 mb)
High resolution image (TIFF 261601 kb)
259_2017_3837_Fig8_ESM.gif (77 kb)
Supplementary Fig. 4

(GIF 76 kb)

259_2017_3837_MOESM5_ESM.tiff (255.5 mb)
High resolution image (TIFF 261601 kb)

References

  1. 1.
    EUCAN | Home page [Internet]. Available from: http://eco.iarc.fr/EUCAN/Default.aspx.
  2. 2.
    Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584–94.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Vansteenkiste J, Crino L, Dooms C, Douillard JY, Faivre-Finn C, Lim E, et al. 2nd ESMO consensus conference on lung cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol. 2014;25:1462–74.CrossRefPubMedGoogle Scholar
  4. 4.
    Zhang M, Zhang Z, Garmestani K, Schultz J, Axworthy DB, Goldman CK, et al. Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc Natl Acad Sci U S A. 2003;100:1891–5.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The eighth edition lung cancer stage classification. Chest. 2017;151:193–203.CrossRefPubMedGoogle Scholar
  6. 6.
    Ost D, Goldberg J, Rolnitzky L, Rom WN. Survival after surgery in stage IA and IB non-small cell lung cancer. Am J Respir Crit Care Med. 2008;177:516–23.CrossRefPubMedGoogle Scholar
  7. 7.
    Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, Van Stiphout RGPM, Granton P, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012;48:441–6.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Sollini M, Cozzi L, Antunovic L, Chiti A, Kirienko M. PET Radiomics in NSCLC: state of the art and a proposal for harmonization of methodology. Sci Rep. 2017;7:358.Google Scholar
  9. 9.
    Bashir U, Siddique MM, Mclean E, Goh V, Cook GJ. Imaging heterogeneity in lung cancer: techniques, applications, and challenges. Am J Roentgenol. 2016;207:534–43.CrossRefGoogle Scholar
  10. 10.
    Chalkidou A, O’Doherty MJ, Marsden PK. False discovery rates in PET and CT studies with texture features: a systematic review. PLoS One. 2015;10:1–18.CrossRefGoogle Scholar
  11. 11.
    Rami-Porta R, Crowley J, Goldstraw P. The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg. 2009;15:4–9.PubMedGoogle Scholar
  12. 12.
    Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2014;42:328–54.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Orlhac F, Nioche C, Buvat I. Technical Appendix — Local Image Features Extraction — — LIFEx —. 2016.Google Scholar
  14. 14.
    Buvat I, Orlhac F, Soussan M. Tumor texture analysis in PET: where do we stand? J Nucl Med. 2015;56:1642–4.CrossRefPubMedGoogle Scholar
  15. 15.
    Uramoto H, Tanaka F. Recurrence after surgery in patients with NSCLC. Transl Lung Cancer Res. 2014;3:242–9.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Hellmann MD, Chaft JE, William WN, Rusch V, Pisters KMW, Kalhor N, et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 2014;15:1–17.CrossRefGoogle Scholar
  17. 17.
    Velez-Cubian FO, Rodriguez KL, Thau MR, Moodie CC, Garrett JR, Fontaine JP, et al. Efficacy of lymph node dissection during robotic-assisted lobectomy for non-small cell lung cancer: retrospective review of 159 consecutive cases. J Thorac Dis. 2016;8:2454–63.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Korasidis S, Menna C, Andreetti C, Maurizi G, D’Andrilli A, Ciccone AM, et al. Lymph node dissection after pulmonary resection for lung cancer: a mini review. Ann Transl Med. 2016;4:368.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Brundage MD. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest. 2002;122:1037–57.Google Scholar
  20. 20.
    Parekh V, Jacobs MA. Radiomics: a new application from established techniques. Expert Rev Precis Med Drug Dev. 2016;1:207–26.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Kim D-H, Jung J, Son SH, Kim C-Y, Hong CM, Oh J-R, et al. Prognostic significance of intratumoral metabolic heterogeneity on 18F-FDG PET/CT in pathological N0 non–small cell lung cancer. Clin Nucl Med. 2015;40:708–14.CrossRefPubMedGoogle Scholar
  22. 22.
    Tixier F, Hatt M, Valla C, Fleury V, Lamour C, Ezzouhri S, et al. Visual versus quantitative assessment of intratumor 18F-FDG PET uptake heterogeneity: prognostic value in non-small cell lung cancer. J Nucl Med. 2014;55:1235–41.CrossRefPubMedGoogle Scholar
  23. 23.
    Apostolova I, Rogasch J, Buchert R, Wertzel H, Achenbach HJ, Schreiber J, et al. Quantitative assessment of the asphericity of pretherapeutic FDG uptake as an independent predictor of outcome in NSCLC. BMC Cancer. 2014;14:896.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Desseroit M-C, Visvikis D, Tixier F, Majdoub M, Perdrisot R, Guillevin R, et al. Development of a nomogram combining clinical staging with (18)F-FDG PET/CT image features in non-small-cell lung cancer stage I-III. Eur J Nucl Med Mol Imaging. 2016;43:1477–85.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Larue RTHM, Defraene G, De Ruysscher D, Lambin P, Van Elmpt W. Quantitative radiomics studies for tissue characterization: a review of technology and methodological procedures. Br J Radiol. 2017;90:20160665.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Carvalho S, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014;5:4006.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Coroller T, Grossmann P, Hou Y, Rios Velazquez E, Leijenaar RT, Hermann G, et al. CT-based radiomic signature predicts distant metastasis in lung. Radiother Oncol. 2015;114:345–50.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Yuan M, Zhang Y-D, Pu X-H, Zhong Y, Li H, Wu J-F, et al. Comparison of a radiomic biomarker with volumetric analysis for decoding tumour phenotypes of lung adenocarcinoma with different disease-specific survival. Eur Radiol. 2017;In press.Google Scholar
  29. 29.
    Parmar C, Leijenaar RT, Grossmann P, Rios-Velazquez E, Bussink J, Rietveld D, et al. Radiomic feature clusters and prognostic signatures specific for lung and head & neck cancer. Sci Rep. 2015;5:11044.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    van Timmeren JE, Leijenaar RTH, van Elmpt W, Reymen B, Oberije C, Monshouwer R, et al. Survival prediction of non-small cell lung cancer patients using radiomics analyses of cone-beam CT images. Radiother Oncol. 2017;123:363–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Huynh E, Coroller TP, Narayan V, Agrawal V, Hou Y, Romano J, et al. CT-based radiomic analysis of stereotactic body radiation therapy patients with lung cancer. Int J Radiat. 2016;120:258–66.Google Scholar
  32. 32.
    Li Q, Kim J, Balagurunathan Y, Liu Y, Latifi K, Stringfield O, et al. Imaging features from pre-treatment CT scans are associated with clinical outcomes in non-small-cell lung cancer patients treated with stereotactic body radiotherapy. Med Phys. 2017;44:4341–9.Google Scholar
  33. 33.
    Van Velden FHP, Kramer GM, Frings V, Nissen IA, Mulder ER, De Langen AJ, et al. Repeatability of radiomic features in non-small-cell lung cancer [(18F)]FDG-PET/CT studies: impact of reconstruction and delineation. Mol Imaging Biol. 2016;18:788–95.Google Scholar
  34. 34.
    Yan J, Chu-shern JL, Loi HY, Khor LK, Sinha AK, Quek ST, et al. Impact of image reconstruction settings on texture features in 18 F-FDG PET. J Nucl Med. 2015;56:1667–74.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  1. 1.Department of Biomedical SciencesHumanitas UniversityPieve EmanueleItaly
  2. 2.Radiotherapy and RadiosurgeryHumanitas Clinical and Research CenterRozzanoItaly
  3. 3.Nuclear MedicineHumanitas Clinical and Research CenterRozzanoItaly
  4. 4.Orobix SrlBergamoItaly
  5. 5.Thoracic SurgeryHumanitas Clinical and Research CenterRozzanoItaly
  6. 6.RadiologyHumanitas Clinical and Research CenterRozzanoItaly

Personalised recommendations